"NEW NORMAL” FOR THE NEW JUDICIARY? INTERSECTIONS BETWEEN ROBINSON CRUSOE AND THE DIFFERENT LITIGANTS IN THE ACCESS TO JUSTICE DURING (AND AFTER) PANDEMIC

This paper searches to confront the main characters of the book Robinson Crusoé, by Daniel Defoe, and the users of the justice system, based on the dilemmas and impositions of the Pandemic of Covid-19, which plagues the whole world. The particularities of the characters Robinson Crusoé and Friday, in view of the need to constantly adapt to new ways of life, were the argument for contextualization, already felt, with the differences between the usual litigants and eventual litigants in the access to justice. The relationship between law and literature, in this case, sought to shed light on aspects related to the need to readjust different litigants for full access to justice, considering the impacts of Pandemic on jurisdictional activity. The scientific method used in the research was the inductive one, by the analysis of the particularities of the characters and the different litigants, as true premises, to determine the different ways of readjusting to the new realities for each one, and what is the impact of these differences on access to justice. So, it was possible to demonstrate that important differences persist between the different litigants in the new jurisdictional reality, urging the adoption of measures that reduce the disparity. © 2022, Universidade do Estado do Rio de Janeiro. All rights reserved.

Corporate Social Responsibility in Times of Epidemic Outbreaks: A Case Study from the Hospitality Industry in Spain

Corporate social responsibility (CSR) is increasingly seen as a key aspect of business management. The rapid spatial spread of the COVID-19 outbreak led to border closures and mandatory mass quarantine. In this context, sectors such as the hospitality industry have been actively involved in various CSR activities, providing infrastructure and resources to help governments and societies cope with the pandemic. This study examines the different effects of CSR activities in the context of the COVID-19 outbreak, both from a business and institutional perspective. A qualitative research design has been chosen for this purpose, based on the analysis of in-depth qualitative interviews with the CEO and senior executives of three international hotel chains in Spain. The results reveal that CSR activities have contributed to containing the pandemic by helping to reduce the collapse of healthcare, as well as improving the organization's performance in terms of reputation and image. © The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.

Impact of Hiv Infection on Mpox-Related Hospitalizations in Brazil

Background: Late presentation to care remains a major public health problem in Brazil, despite the countrys longstanding commitment to universal access to ART to all PLWH. The COVID-19 pandemic severely hit the country and further impacted the HIV care continuum, with worse disparities observed by gender and sexual orientation. By December 28th 2022, Brazil reported 10,493 and 14 mpox cases and deaths ranking second globall. Although mpox lethality is low, HIV-related immunosuppression may negatively impact mpox outcomes, increasing hospitalizations and fatalities. We aim to describe mpox hospitalization rates and explore the impact of HIV-infection on mpox-related hospitalizations and clinical outcomes. Method(s): Prospective, observational cohort study of individuals with confirmed mpox infection followed at the major mpox referral center in Rio de Janeiro, Brazil. Demographic and clinical data including reasons for hospitalization were systematically collected. Chi-squared or Fisher's exact tests for qualitative variables and the Moods median test for quantitative variables were used. Result(s): From June 12 to December 12, 2022, 402 participants had a laboratory-confirmed mpox diagnosis. Median age was 34 years, 365 (91%) were cisgender men, and 197 (49%) were PLWH. Overall, 39 (10%) participants were hospitalized due to mpox-related causes;20 (51%) were PLWH. All PLWH with CD4 counts< 200 cells/mm3 required hospitalization. Compared to nonhospitalized PLWH, a higher proportion of hospitalized PLWH had concomitant opportunistic infections (4/20 [20%] vs. 1/177 [0.6%];p< 0.001), were not virologically suppressed (7/20 [35.0%] vs. 22/177 [15.3%];p=0.1) and were not on ART (4/20 [20%] vs. 15/177 [7.6%];p=0.03). Among all hospitalized participants, PLWH were more frequently hospitalized due to severe proctitis than HIV-negative participants (12/20 [60%] vs. 5/19 [26.3%];p=0.03), with no differences regarding hospitalizations for pain control (Table). PLWH accounted for all cases of hospitalized individuals who required intensive care support (n=4), had deep tissue involvement (n=3) and had a mpox related death (n=2). Conclusion(s): Our findings suggest an association between worse outcomes in the HIV care continuum and mpox-related hospitalizations. Advanced immunosuppression (CD4< 200) contributed to more severe clinical presentations and death. Public health strategies to mitigate HIV late presentation and the negative impact of the COVID-19 pandemic to the HIV care continuum are urgently needed. Sociodemographic and clinical characteristics of mpox cases according to HIV and hospitalization status.

Telepsychology for psychotherapists: lessons learned in times of Covid-19

The necessary health measures proposed to mitigate the viral spread of SARS-CoV-2, such as physical distancing and quarantines, have had an impact not only on the mental health of the population but have also forced changes in the provision of psychological services. The present study aims to gather essential information on the concept, advantages, disadvantages, uses and recommendations of telepsychology in times of COVID-19. To this end, a systematic review of the scientific evidence available in the Scopus, PubMed and Web of Science databases was carried out. Among the results, accessibility, reduction of stigma and flexibility in its application are highlighted. Limitations such as insecurity of data privacy, access barriers and low clinical training in the competencies required for this format are also mentioned. On the other hand, favorable evidence was found for its use in the treatment of post-traumatic stress disorder, panic and agoraphobia, generalized anxiety, and trauma. It is concluded that psychotherapeutic intervention through telepsychology, in consideration of certain recommendations and critical suggestions, can offer satisfactory results for the patient and therapist and be suitable for various age ranges and disorders. © 2022, Sociedad Interamericana de Psicologia. All rights reserved.

Facteurs prédictifs d'une poussée de psoriasis après une infection par le SARS-CoV-2 chez l'enfant

Introduction: La pandémie à SARS-CoV-2 a été source de nombreuses questions quant à l'impact de l'infection sur les dermatoses inflammatoires chroniques, et de l'impact des traitements de ces dermatoses sur la sévérité de l'infection. Le registre international Chi-PsoCov (enfants psoriasique souffrant de psoriasis et ayant développé une infection à SARS-CoV-2) a permis de montrer que les biothérapies n'augmentaient pas le risque de formes sévères de COVID-19 chez les enfants atteints de psoriasis. Par ailleurs, il était montré que le COVID-19 était responsable du développement de psoriasis de novo ou de l'aggravation d'un psoriasis connu chez certains enfants.Dans cette partie du travail nous nous sommes concentrés sur les enfants ayant développé une poussée de psoriasis après l'infection : aspects phénotypiques des poussées, et recherche de facteurs de risque liés à la maladie, au psoriasis, ou aux traitements, associés à l'aggravation du psoriasis après l'infection. Matériel et méthodes: Les données ont été collectées de février 2021 à mai 2022 en provenance de 14 pays. Les enfants étaient inclus s'ils avaient moins de 18 ans, un antécédent de psoriasis ou psoriasis apparu dans le moins suivant l'infection COVID-19, et avaient été infectés par le SARS-CoV-2 avec ou sans symptômes. Les enfants ayant développé un psoriasis de novo étaient exclus de cette étude. Résultats: Sur les 152 inclusions du registre Chi-PsoCov, dix enfants ont développé un psoriasis dans le mois suivant l'infection et n'ont pas été retenus dans ce travail. L'analyse a porté sur 135 enfants ayant développé 142 COVID-19. Le psoriasis était stable dans 120 cas (84,5 %) et s'aggravait dans le mois suivant l'infection dans 22 cas (15,5 %).Dans 20 cas, lors de la poussée, le phénotype était inchangé, et dans 2 cas, il y avait un changement de phénotype : psoriasis en plaques en psoriasis en gouttes (n = 1) ou inversé (n = 1).Ni les caractéristiques démographiques, ni les aspects du psoriasis (notamment psoriasis actif vs en rémission), ni la sévérité de l'infection à SARS-CoV-2 n'étaient associés à des poussées de psoriasis. Seule l'utilisation de traitements systémiques du psoriasis, conventionnels ou biothérapies, lors de l'infection semblait protectrice de la survenue de poussées (50,0 % dans le groupe stable vs 27,3 % dans le groupe poussées, p = 0,049). Discussion: L'infection à SARS-CoV-2 est responsable dans environ 15 % des cas de poussées de psoriasis. Dans la grande majorité des cas, le phénotype précédent l'infection est conservé. Ces poussées ne sont pas associées à la sévérité du psoriasis, de l'infection ou autres paramètre cliniques. Seuls les traitements systémiques semblent réduire ce risque, probablement en « contrôlant » la poussée. Il est possible qu'une susceptibilité d'ordre génétique, non explorée ici, explique aussi cette susceptibilité à l'infection.

COVID-19 et psoriasis de l'enfant : facteurs associés à une évolution défavorable de la COVID-19 et impact de l'infection sur le psoriasis. Registre Chi-PsoCov

Introduction: La pandémie à SARS-CoV-2 a soulevé de nombreuses questions sur la prise en charge des maladies chroniques et leurs traitements. Les données concernant l'utilisation des biothérapies chez les adultes atteints de psoriasis sont rassurantes, mais manquent chez l'enfant. Par ailleurs, l'infection à SARS-CoV-2 pourrait influencer l'évolution du psoriasis chez l'enfant. L'objectif de cette étude était d'évaluer l'impact de l'infection à SARS-CoV-2 sur le psoriasis, et la sévérité de l'infection selon le traitement systémique reçu. Matériel et méthodes: Les données ont été collectées de février 2021 à février 2022 en provenance de 14 pays. Les enfants étaient inclus s'ils avaient moins de 18 ans, un antécédent de psoriasis ou apparu dans le moins suivant l'infection COVID-19, et avaient été infectés par le SARS-CoV-2 avec ou sans symptômes. Résultats: Au total, 117 enfants ont été inclus (filles : 49,6 %, âge moyen : 12,4 ans) avec 120 infections) SARS-CoV-2. La principale forme de psoriasis était le psoriasis en plaques (69,4 %) ;le psoriasis était actif avant l'infection dans 70,1 % des cas. La majorité des enfants ne prenaient pas de traitement systémique au moment de l'infection (54,2 %), 33 enfants (28,3 %) étaient sous biothérapie (principalement anti-TNF alpha et ustékinumab), et 24 (20,0 %) sous traitement systémique conventionnel (principalement méthotrexate). L'infection était confirmée chez 106 enfants (88,3 %) et 3 ont eu la maladie 2 fois (1 enfant asymptomatique sous ustékinumab et 2 enfants symptomatiques sans traitement systémique). L'infection était symptomatique chez 75 enfants (62,5 %) avec une durée moyenne des symptômes de 6,5 jours, significativement plus longue chez les enfants sous traitement systémique conventionnel (p = 0,002) ou sans traitement systémique (p = 0,006) par rapport aux enfants traités par biothérapies. Six enfants ont nécessité une hospitalisation, dont un enfant en réanimation ;ils étaient plus fréquemment sous traitements systémiques conventionnels par rapport aux autres enfants (p = 0,01), et principalement sous méthotrexate (p = 0,03). Aucun enfant sous biothérapie n'a été hospitalisé, et aucun décès n'a été rapporté.Après l'infection, le psoriasis s'est aggravé dans 17 cas (15,2 %), sans modification du phénotype sauf pour un enfant avec un psoriasis initialement en plaques qui a eu suite à l'infection une poussée de psoriasis en gouttes. Neuf enfants (8,0 %) ont développé un psoriasis de novo dans le mois qui a suivi l'infection, plus souvent un psoriasis en gouttes (p = 0,01) par rapport aux enfants ayant un antécédent connu de psoriasis. Ces enfants avaient un antécédent familial de psoriasis dans 75,0 % des cas. Discussion: L'utilisation des biothérapies semble rassurante sans augmentation du risque de forme sévère de COVID-19 chez les enfants atteints de psoriasis. L'infection à SARS-CoV-2 était responsable du développement de psoriasis de novo ou de l'aggravation d'un psoriasis connu chez certains enfants.

University teaching innovation in the covid-19 dra: A systematic literature review

This case study is based on contextualizing and responding to some dichotomies in education at all levels, focusing specifically on the university level and how the education system in general, and teachers in particular, can and should innovate in order to offer quality education to students. These students have been adapting to the latest technological advances. This chapter gives as an example case studies where it is demonstrated that these technological advances are not the exclusive focus on which educational innovation should be based. © 2022, IGI Global. All rights reserved.

Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry).

BACKGROUND: The COVID-19 pandemic has raised questions regarding the management of chronic skin diseases, especially in patients on systemic treatments. Data concerning the use of biologics in adults with psoriasis are reassuring, but data specific to children are missing. Moreover, COVID-19 could impact the course of psoriasis in children. OBJECTIVES: The aim of this study was therefore to assess the impact of COVID-19 on the psoriasis of children, and the severity of the infection in relation to systemic treatments. METHODS: We set up an international registry of paediatric psoriasis patients. Children were included if they were under 18 years of age, had a history of psoriasis, or developed it within 1 month of COVID-19 and had COVID-19 with or without symptoms. RESULTS: One hundred and twenty episodes of COVID-19 in 117 children (mean age: 12.4 years) were reported. The main clinical form of psoriasis was plaque type (69.4%). Most children were without systemic treatment (54.2%); 33 (28.3%) were on biologic therapies, and 24 (20%) on non-biologic systemic drugs. COVID-19 was confirmed in 106 children (88.3%) and 3 children had two COVID-19 infections each. COVID-19 was symptomatic for 75 children (62.5%) with a mean duration of 6.5 days, significantly longer for children on non-biologic systemic treatments (P = 0.02) and without systemic treatment (P = 0.006) when compared with children on biologics. The six children who required hospitalization were more frequently under non-biologic systemic treatment when compared with the other children (P = 0.01), and particularly under methotrexate (P = 0.03). After COVID-19, the psoriasis worsened in 17 cases (15.2%). Nine children (8%) developed a psoriasis in the month following COVID-19, mainly a guttate form (P = 0.01). DISCUSSION: Biologics appear to be safe with no increased risk of severe form of COVID-19 in children with psoriasis. COVID-19 was responsible for the development of psoriasis or the worsening of a known psoriasis for some children.

PrEP LONG-TERM ENGAGEMENT among MSM and TGW in LATIN AMERICA: The ImPrEP STUDY

Background: Although cisgender MSM (cis-MSM) and transgender women (TGW) suffer the highest burden due to the HIV epidemic in Latin America (LA), PrEP implementation is limited. ImPrEP was an implementation study to assess safety and feasibility of same-day PrEP initiation (daily-oral TDF/FTC) for cis-MSM and TGW vulnerable to HIV infection in Brazil, Peru and Mexico;results on factors associated with long-term PrEP engagement (LTPE) and HIV incidence are reported here. Methods: Eligible cis-MSM and TWG (HIV-negative, ≥18 years-old, reporting 1+ risk criteria) were screened and enrolled on the same-day, receiving a 30-day PrEP supply. Follow-up visits were scheduled at week 4 after enrollment and quarterly thereafter. Main outcomes were LTPE (3+ follow-up visits within 52 weeks of enrollment) and HIV incidence. A multivariable model controlling for country, education, gender, substance use, STIs, and self-reported adherence is presented. Results: From March 2018-June 2021, 9522 participants were enrolled (Brazil: 3928, Mexico: 3301, Peru: 2293), with 12348.92 person-years (PY) follow-up;follow-up time accrued for LTPE analysis affected by Covid-19 restrictions was shorter in Brazil than in Mexico and Peru. Overall, 26% were aged 18-24, 94.3% cis-MSM, 5.7% TGW, 73.2% non-white and 76.0% >secondary education;92.8% reported condomless anal sex (CAS), 17.3% sex-work, 57.8% had >5 sex partners. Overall, 8.8% attended only the enrollment visit and 68.2% showed LTPE (Brazil:80.1%;Mexico:67.2%;Peru:45.0%). Participants aged 18-24 years (aOR 0.53[95%CI:0.46-0.62]), 10 sex partners (aOR 1.48[95%CI:1.28-1.70]), reporting receptive CAS (aOR 1.24[95%CI:1.12-1.39]), complete adherence at week-4 (aOR:3.11[95%CI:2.79-3.45]) and CAS with HIV+ partner (aOR:1.48[95%CI:1.28-1.71]) were more likely. HIV incidence was 0.84/100 PY (95% CI:0.69-1.02), higher in Peru, among TGW and 18-24 years-old participants. Conclusion: Same-day PrEP is feasible and safe among cis-MSM and TGW in LA. Overall LTPE was high;COVID-19 restrictive measures may partially explain the differences across countries. Social and structural levels of HIV risk need to be addressed for full PrEP benefits realization.

Coping with COVID-19 in Patients with Lung Cancer

Background/Purpose: Prior to the pandemic, patients with lung cancer commonly experienced stigmatization, high symptom burden, and unmet supportive care needs, placing them at increased risk for psychosocial morbidities during COVID-19. These risks necessitate investigation into how lung cancer patients have been coping during the pandemic. Methods: This study investigated COVID-19-related burden and behavioral coping utilized by 65 lung cancer patients receiving treatment at an NCI-designated Comprehensive Cancer Center between August 2020 and June 2021. Measurements included selfreport demographics, COVID-19 burden (Impact of COVID-19 Pandemic in Cancer Survivors Questionnaire, Penedo et al., 2020), psychosocial well-being (PROMIS Anxiety4a and Depression4a), and coping strategies (Brief COPE, Carver 1997). Results: Most participants identified as female (n = 43), non- Hispanic White (n = 53), partnered (n = 38), and diagnosed with Non-Small Cell Lung Cancer (n = 45);and most reported feeling anxious about contracting COVID-19 (n = 38;58.5%) and concerned that their cancer status increased their risk of dying (n = 47;72.3%). However, average PROMIS T-scores for anxiety (M = 53.59, SD = 9.05) and depression (M = 51.19, SD = 8.30) were similar to normed national averages. Participants primarily endorsed acceptance, active coping, and the use of emotional support coping strategies. Higher total COVID-19 burden was associated with greater use of venting, behavioral disengagement, and self-blame coping strategies. Higher total COVID-19 burden was associated with greater anxiety (r = 0.489;p < 0.001) and depression (r = 0.414;p < 0.001). Greater anxiety was associated with higher use of religion, venting, denial, substance use, and selfblame coping strategies. Greater depression was associated with greater reliance on instrumental support, venting, denial, substance use, and self-blame strategies. Conclusions and Implications: Participants recognized their heightened risks and utilized effective coping strategies during COVID-19. Use of acceptance, active coping, and emotional support may impact lung cancer patients' appraisals of COVID-19 and psychosocial wellbeing.

Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey.

BACKGROUND: Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse coronavirus disease 2019 (COVID-19) outcomes compared with patients receiving no systemic treatments. OBJECTIVES: We used international patient survey data to explore the hypothesis that greater risk-mitigating behaviour in those receiving targeted therapies may account, at least in part, for this observation. METHODS: Online surveys were completed by individuals with psoriasis (globally) or rheumatic and musculoskeletal diseases (RMDs) (UK only) between 4 May and 7 September 2020. We used multiple logistic regression to assess the association between treatment type and risk-mitigating behaviour, adjusting for clinical and demographic characteristics. We characterized international variation in a mixed-effects model. RESULTS: Of 3720 participants (2869 psoriasis, 851 RMDs) from 74 countries, 2262 (60·8%) reported the most stringent risk-mitigating behaviour (classified here under the umbrella term 'shielding'). A greater proportion of those receiving targeted therapies (biologics and Janus Kinase inhibitors) reported shielding compared with those receiving no systemic therapy [adjusted odds ratio (OR) 1·63, 95% confidence interval (CI) 1·35-1·97]. The association between targeted therapy and shielding was preserved when standard systemic therapy was used as the reference group (OR 1·39, 95% CI 1·23-1·56). Shielding was associated with established risk factors for severe COVID-19 [male sex (OR 1·14, 95% CI 1·05-1·24), obesity (OR 1·37, 95% CI 1·23-1·54), comorbidity burden (OR 1·43, 95% CI 1·15-1·78)], a primary indication of RMDs (OR 1·37, 95% CI 1·27-1·48) and a positive anxiety or depression screen (OR 1·57, 95% CI 1·36-1·80). Modest differences in the proportion shielding were observed across nations. CONCLUSIONS: Greater risk-mitigating behaviour among people with IMIDs receiving targeted therapies may contribute to the reported lower risk of adverse COVID-19 outcomes. The behaviour variation across treatment groups, IMIDs and nations reinforces the need for clear evidence-based patient communication on risk-mitigation strategies and may help inform updated public health guidelines as the pandemic continues.

Oral manifestations associated to SARS-COV-2: A literature review

Aim: Identify the main oral manifestations and describe their location in the oral cavity, in patients with COVID-19. Methods: The literature search was developed in the following databases: PubMed, Medline, LILACS, LIVIVO, Web of Science and SciELO;combining the following words: oral mucosa, oral mucosa lesion, oral manifestations, COVID-19 and SARS-CoV-2. Duplicated articles were eliminated, and then a preselection of articles was made. Finally, inclusion and exclusion criteria were applied. Results: 47 articles were included in this study. The main oral manifestations in patients with COVID-19 are taste disorders, xerostomia, ulcers, vesicles, and others;with location in different areas of the oral mucosa. Conclusion: More studies are needed to conceive the possible oral pathogenesis of SARS-CoV-2. Moreover, the role of the dentist in the multidisciplinary team and teleconsultation are highlighted.